Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Seerapani Gopaluni, Oliver Flossmann, Mark A Little, Paul O'Hara, Pirow Bekker, David Jayne & European Vasculitis Society
Introduction: The treatment of ANCA associated vasculitis (AAV) aims to suppress disease activity and prevent subsequent disease flare. We explored the association of early disease control with long-term outcomes to validate early disease control as end-points for future clinical trials. Methods: Data from four inception trials (CYCAZAREM, NORAM, MEPEX & CYCLOPS) and subsequent long-term registry data were studied. Clinical parameters at baseline, three and six months were assessed to study the risk of death and...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.